Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]
Discontinued
Reference number: GID-TA10688
Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.